IndustryCompany release

Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND

🇺🇸 Calidi Biotherapeutics, Inc. (CLDI) · Fri 13 Nov 2026

The oncolytic virus developer reports $3.9M in cash, a headcount-led restructuring expected to save about $3M a year, and a first-patient dose for CLD-401 targeted for H2 2027.

Calidi Biotherapeutics reported a net loss of $3.6M for the third quarter of 2026 on 13 November, alongside a restructuring and a small equity raise. The company ended the period with cash of $3.9M.

General and administrative expenses fell 39%. On 6 November, Calidi carried out a restructuring, mainly through headcount reductions, which it expects to save about $3M a year. It also raised $1.2M through an at-the-market registered direct offering.

The company's lead oncolytic virus candidate, CLD-401, remains in IND-enabling studies. Preclinical data on the candidate were presented at ESMO 2026. Calidi is targeting dosing of the first patient in the second half of 2027.

The source material available to VigiEye was limited to the company's summary of results, so further detail on the financials, the restructuring and the development timeline is not included here.

What it means for your team

  • For regulatory teams, CLD-401 has not yet reached the clinic: it is still in IND-enabling studies, with first-patient dosing targeted for H2 2027.
  • Cash of $3.9M and a $1.2M raise point to a very short financial runway, which partners and suppliers may wish to factor into counterparty assessments.
  • Headcount cuts at a small developer can affect capacity for regulatory and quality work, so teams working with Calidi should confirm contact points and timelines.

Company's press release (SEC filing): Calidi Biotherapeutics, Inc. ↗

Article written by VigiEye from the official source (Calidi Biotherapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →